- Home
- SNY vs KZR Comparison
SNY vs KZR Comparison
Compare SNY & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- KZR
- Stock Information
- Founded
- SNY 1994
- KZR 2015
- Country
- SNY France
- KZR United States
- Employees
- SNY N/A
- KZR N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- SNY Health Care
- KZR Health Care
- Exchange
- SNY Nasdaq
- KZR Nasdaq
- Market Cap
- SNY 116.1B
- KZR 29.7M
- IPO Year
- SNY N/A
- KZR 2018
- Fundamental
- Price
- SNY $49.77
- KZR $6.23
- Analyst Decision
- SNY Buy
- KZR Hold
- Analyst Count
- SNY 4
- KZR 4
- Target Price
- SNY $61.50
- KZR $6.00
- AVG Volume (30 Days)
- SNY 3.9M
- KZR 453.7K
- Earning Date
- SNY 10-24-2025
- KZR 11-11-2025
- Dividend Yield
- SNY 3.22%
- KZR N/A
- EPS Growth
- SNY 118.56
- KZR N/A
- EPS
- SNY 8.65
- KZR N/A
- Revenue
- SNY $53,714,621,258.00
- KZR N/A
- Revenue This Year
- SNY $1.40
- KZR N/A
- Revenue Next Year
- SNY $6.67
- KZR N/A
- P/E Ratio
- SNY $5.74
- KZR N/A
- Revenue Growth
- SNY 15.65
- KZR N/A
- 52 Week Low
- SNY $44.62
- KZR $3.53
- 52 Week High
- SNY $60.12
- KZR $8.45
- Technical
- Relative Strength Index (RSI)
- SNY 56.20
- KZR 82.29
- Support Level
- SNY $48.54
- KZR $4.10
- Resistance Level
- SNY $50.72
- KZR $4.45
- Average True Range (ATR)
- SNY 0.69
- KZR 0.31
- MACD
- SNY 0.15
- KZR 0.26
- Stochastic Oscillator
- SNY 60.09
- KZR 95.47
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.